OK Biotech Co., Ltd.
4155.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$0.26
Average shareholder expectationRevenue Estimate
$296.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$0.27
Average shareholder expectationRevenue Estimate
$296.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About OK Biotech Co., Ltd.
62 employees
CEO: Jia-De Lai OK Biotech Co., Ltd., established in 2006 and based in Hsinchu City, Taiwan, is a global producer and vendor of blood glucose meters. Its product line further encompasses nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers.